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Abstract 
Objective: Cognitive impairment is a key cause of disability after traumatic brain injury (TBI) but 
relationships with overall functioning in daily life are often modest. The aim is to examine cognition 
at different levels of function and identify domains associated with disability.  
Methods: 1554 patients with mild to severe TBI were assessed at six months post-injury on the 
Glasgow Outcome Scale - Extended (GOSE), the Short Form-12v2, and a battery of cognitive tests. 
Outcomes across GOSE categories were compared using ANCOVA adjusting for age, sex, and 
education. 
Results: Overall effect sizes were small to medium, and greatest for tests involving processing speed 
( ηp
2 0.057 to 0.067) and learning and memory (ηp
2 0.047 to 0.051). Deficits in cognitive performance 
were particularly evident in patients who were dependent (GOSE 3 or 4) or who were unable to 
participate in one or more major life activities (GOSE 5). At higher levels of function (GOSE 6 to 8), 
cognitive performance was surprisingly similar across categories. There were decreases in 
performance even in patients reporting complete recovery without significant symptoms. Medium 
to large effect sizes were present for summary measures of cognition (ηp
2 0.111), mental health (ηp
2 
0.131) and physical health (ηp
2 0.252).  
Conclusions: This large-scale study provides novel insights into cognitive performance at different 
levels of disability and highlights the importance of processing speed in function in daily life. At 
upper levels of outcome any influence of cognition on overall function is markedly attenuated and 
differences in mental health are salient.  
Key words: Traumatic brain injury, cognition, functional outcome, prospective observational study 
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INTRODUCTION 
TBI is a leading cause of disability, creating a huge burden on individuals and society.1 Over half of 
patients presenting with mild TBI report limitations in function at 6 months,2 and disability may 
persist for many years.3 Despite a high prevalence, much of this disability is unexplained, 
representing a barrier to effective treatment.4 Studies show that cognitive test performance is 
associated with aspects of function in daily life after TBI, including independence and return to 
work.5,6 However, the relationship between cognitive impairment and everyday functioning is 
incompletely understood.  
It is often assumed that cognitive impairment will have a strong influence on overall functional 
outcome; however, reported associations are typically modest.6 Chaytor et al5 found that cognitive 
test performance accounted for 20% to 30% of outcome variance on the Functional Status Exam, 
which provides a multi-domain evaluation of function. A systematic review7 of studies relating 
cognition to global functional outcome found that multiple dimensions of cognition were associated 
with the Glasgow Outcome Scale – Extended (GOSE), explaining 31% of the variance in outcome. 
However, these studies were relatively small, with a median sample size of 135 (range 37-334).7 As a 
consequence, there is little information concerning cognitive performance at different levels of 
functional recovery.  
Past work indicates that cognitive impairment is present in individuals who are unable to return to 
work, and is even greater in those that are dependent. However, the role of cognition in higher 
levels of functional recovery is unclear. Impaired performance on cognitive tests has been reported 
in individuals graded as Good Recovery on the GOSE.8 Possible explanations include unrecognized 
cognitive impairment identified by objective testing, poorly matched normative data for tests, or use 
of a coarse global scale.  
We address these issues by studying the relationship of the GOSE to cognitive assessment in a 
cohort of patients who form part of the Collaborative European NeuroTrauma Effectiveness 
Research (CENTER-TBI) project (www.center-tbi.eu).9 Over 1500 patients had detailed cognitive 
assessment at 6 months, providing an opportunity for more fine-grained analyses than hitherto 
possible. The aim of our study was to better characterize the association between cognitive 




CENTER-TBI recruited 4509 patients to core data collection from 65 centres.9 Criteria for inclusion 
were: a diagnosis of TBI, clinical indication for a CT scan, presentation within 24 hours of injury, and 
consent obtained.9 The study enrolled patients from emergency rooms, hospital admissions, and 
intensive care units. Participants were only excluded if they had a severe pre-existing neurological 
disorder that would confound outcome assessments. The sample thus included patients with very 
mild injuries, as well as those at the most severe end of the spectrum. Analyses here were confined 
to patients aged 16 or older who had been assessed on the GOSE at the six-month time point and 
had completed one or more computerized cognitive tests (Supplementary figure S1). The last 
criterion was included to select the main group that had contributed cognitive data. 
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Procedure 
Demographic and clinical data were recorded during the acute stage. A composite baseline Glasgow 
Coma Scale (GCS) was created using assessment at the time of emergency room (ER) discharge as 
the preferred measure, and where that was not available, working progressively earlier in time. The 
first Computed Tomography (CT) scan after injury was used to identify whether imaging 
abnormalities were present.  
All patients were scheduled for follow-up at the six-month time point, which is the focus of the 
current study. When translations of assessments were not available from the publisher, the material 
originally in English was translated into local languages using a process of linguistic validation based 
on guidelines.10 Patients agreeing to neuropsychological assessment were seen face-to-face. 




The battery consisted of the Rey Auditory Verbal Learning Test (RAVLT), the Trail Making Task (TMT) 
part A and B, and 6 subtests from the Cambridge Neuropsychological Test Automated Battery 
(CANTAB). The CANTAB tasks are language independent, facilitating multinational use. Details of the 
assessments are provided in Table 1 and in supplementary methods. Cognitive tests covered areas 
known to be affected by TBI, including memory and learning, processing speed, attention, and 
aspects of executive functions. Procedures for conducting testing were specified in a study manual, 
and assessors were given face to face training in testing. 
Table 1. Cognitive tests included in the CENTER-TBI battery, the domains that they primarily assess, and the 
specific measures that were used in analyses. 
Test Domains Measure 
CANTAB Paired Associate 
Learning (PAL) 
Visual learning and 
memory 
Total errors adjusted (i.e. errors for all trials, 
allowing for trials not completed) 
Rey Auditory-Verbal Learning 
Task (RAVLT) 
Verbal learning and 
memory 
Total correct words recalled for the 15-item 
principal list over 5 trials 
Trail Making Test A (TMT A) Attention and processing 
speed 
Time to draw lines between 25 numbers in 
sequence (secs) 
Trail Making Test B (TMT B) Attention and processing 
speed, task switching 
Time to draw lines in alternating sequence 
between 13 numbers and 12 letters (secs) 
CANTAB Choice Reaction Time 
(RTI)  
Processing speed Median decision time for correct responses 
(msec) 
Motor speed Median movement time for correct responses 
(msec) 
CANTAB Rapid Visual Processing 
(RVP) 
Sustained attention A’ (A prime): accuracy of target detection 
calculated from hits and correct rejections 
Sustained attention Latency of correct responses (msec) 
CANTAB Attention Switching Task 
(AST) 
Attention, task switching Total correct responses 
Attention, task switching  Median latency of correct responses (msec) 
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CANTAB Spatial Working Memory 
(SWM) 
Strategy and working 
memory 
Between errors: number times a search is 
incorrectly repeated for the same location.  
CANTAB Stockings of Cambridge 
(SOC) 
Planning, problem solving Trials solved in the minimum possible moves 
 
Global functional outcome and health-related quality of life 
Glasgow Outcome Scale – Extended. The GOSE was assessed either as a structured interview12 or a 
questionnaire completed by the patient or carer.13 A composite GOSE was created by scoring both 
the interview and the questionnaire centrally, and combining the ratings, with the interview as the 
preferred source (94% of assessments). Outcome categories on the GOSE are: Upper Good Recovery 
(8), Lower Good Recovery (7), Upper Moderate Disability (6), Lower Moderate Disability (5), Upper 
Severe Disability (4), and Lower Severe Disability (3). Criteria used to assign the categories are 
detailed in supplementary methods (Table S1). 
Short-Form-12v2 (SF-12v2). The SF-12v2 is a 12-item health-related quality of life assessment 
completed by the patient.14 The Physical Component Summary (PCS) provides an overall measure of 
global functional outcome, while the Mental Component Summary (MCS) assesses outcome related 
to aspects of mental health. When the SF-12v2 had not been completed, but the Short Form-36v2 
was available, we used the 12 corresponding items from the latter to derive summary scores. 
Outcomes are expressed as T-scores (standardized using the normative sample to a mean of 50 and 
standard deviation (SD) of 10).  
Statistical analyses 
A reference group was created by dividing patients who reported complete recovery (GOSE 8) into 
two groups: GOSE 8a consisted of patients with GCS=15 at recruitment and no abnormality on early 
CT, while GOSE 8b consisted of remaining patients with Upper Good Recovery. The reference group 
was GOSE 8a, and our expectation was that individuals in this group would be at the very mildest 
end of the spectrum of TBI severity, and therefore least likely to have persisting cognitive 
impairment. These “ultra-mild” patients are matched to the whole group with respect to the 
experience of the clinical processes associated with TBI. As a check on the reference group, 
previously published normative data was used to calculate expected mean scores allowing for the 
age distribution of the patient group. Demographic and clinical characteristics of the GOSE 8a and 
GOSE 8b subgroups were compared using chi-square for categorical variables and t-testing for age. 
Distributions of scores on individual tests were inspected, and a log 10 transform was applied to 
reduce unequal variance in measures from the following: Trail Making A and B, RTI, PAL, RVP, SWM 
and AST latency. To provide a common metric for tests, cognitive measures were converted to z-
scores using the mean and standard deviation of the reference group (i.e. group GOSE 8a). Scores 
were coded so that negative values indicated poorer performance than reference. A composite 
cognition score was calculated by averaging z-scores across tests, when six or more cognitive 
outcomes were available. Scores that were one or more SDs below the reference were considered to 
indicate at least borderline cognitive impairment. 
GOSE categories were compared using one-way ANCOVA, adjusting for age, sex and level of 
education. ANCOVA is a linear model, with test score as the dependent variable. Missing values for 
level of education were imputed using the mice function in R to generate ten datasets.15 Outcomes 
were included in the imputation process, but imputed values of outcomes were not used in 
subsequent analyses. Pooled estimates for adjusted means and 95% confidence intervals (CIs) were 
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derived from the ANCOVA. CIs are provided to aid interpretation of the graphed results: differences 
between means are considered to have p<.05 when the CIs overlap less than 50%, and p<.01 when 
they do not overlap.16 The CIs do not make any adjustment for multiple comparisons. Pooled F-
values for the omnibus comparison from the imputed datasets were obtained using the mi.anova 
function in R. Controlling for the family-wise error rate (FWER) the significance threshold is (0.05/15) 
0.0033. Effect sizes from the ANCOVA are partial eta-squared (ηp
2), with a conventional 
interpretation 0.01 = small, 0.06 = medium, and 0.14 = large. We conducted 15 pairwise 
comparisons (12 cognitive tests and 3 composites) of the adjusted means of outcomes for groups 
GOSE 8a and GOSE 8b, and controlled the results for a 15% false discovery rate using the Benjamini 
and Hochberg procedure.17 In contrast to FWER adjustment, this procedure corrects for multiple 
comparisons where differences on specific individual tests are not critical to the overall conclusion.  
Data was collected on an electronic case report form (Quesgen Systems Inc, USA), hosted on the 
International Neuroinformatics Facility (INCF) platform and extracted via INCF Neurobot (INCF, 
Sweden). Version 2.1 of the CENTER-TBI database was downloaded on 10th November 2019, and 
analyses were conducted using SPSS 25.0 and R 3.5.1 (R Foundation for Statistical Computing, 
Vienna, Austria).  
Ethical approval 
Ethical approval was obtained for each recruiting site, and consent was obtained in all patients 
according to national and local procedures.  A complete ethics statement can be found at 
https://www.center-tbi.eu/project/ethical-approval 
RESULTS 
Assessment of cognitive performance at 6 months was carried out in 1554 patients out of 2604 
survivors with a GOSE follow-up. Cognitive test completion rates were influenced by GOSE category 
(see supplementary Table S2): patients with GOSE 3 had the lowest completion rates (8%-21% across 
cognitive tests), followed by patients with GOSE 4 (35%-57%), while completion rates for patients 
with higher GOSE outcomes were substantially greater, and generally around 70% (GOSE 5 59%-74%, 
GOSE 6 65%-81%, GOSE 7, 62%-79%, and GOSE 8, 53% - 69%). In the GOSE 3 category a common 
reason given for non-completion was the presence of cognitive or neurological deficits 
(supplementary Table S2). Over all categories, logistical reasons and patient availability were most 
commonly cited for non-completion.  Since the absolute number of individuals tested in the GOSE 3 
category was small (N=31), GOSE 3 and 4 were combined into one category of patients with severe 
disability (GOSE 3/4, N=115).  
Demographic and clinical information concerning the study sample is given in Table 2, and 
corresponding information for the whole sample and the sample alive and eligible for assessment at 
6 months is provided in supplementary Table S3. Compared to the non-study group, the study 
sample were more likely to have progressed to a higher level of education, and were more likely to 
be working and partnered before injury.  The study group were also less severely injured by GCS and 
AIS criteria than the non-study group, and had better outcomes on the GOSE. Patients who had 
completed some cognitive assessment are therefore a selected subgroup of the eligible sample, 
particularly in relation to injury severity and outcome. 
 
Information concerning the subgroups with Upper Good Recovery (GOSE 8a and GOSE 8b) is given in 
Table 2. There were significant differences between subgroups on variables reflecting severity of 
injury (baseline GCS, care pathway, imaging abnormality, and both head and neck and non-head and 
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neck AIS scores). On demographics, differences for employment history reached significance, but not 
for age, sex, race, level of education, or marital status.  
Table 2. Demographic and clinical characteristics of the study sample, and the two subgroups with GOSE 8 
(Upper Good Recovery). GOSE 8a is used as a reference in subsequent analyses, and consists of patients with 
GCS=15 at recruitment and no abnormality on early CT; GOSE 8b consists of remaining patients with Upper 
Good Recovery. Tests for significance are for comparison of groups GOSE 8a and GOSE 8b. 
 N (%)    
 Study sample GOSE 8a GOSE 8b P 
 (n=1554) (n=301) (n=302)  
Age         
Mean (SD) 47.9 (18.8) 47.5 (18.9) 46.8 (21.2) 0.663 
Sex        
Female 513 (33) 94 (31) 77 (25) 0.141 
Male 1041 (67) 207 (69) 225 (75)  
Race        
Caucasian 1465 (97) 292 (98) 288 (98) 1.00 
Other 38 (3) 6 (2) 6 (2)  
Missing 51  3  8   
Highest level of education        
Primary 182 (13) 29 (10) 44 (16) 0.056 
Secondary 468 (33) 90 (32) 90 (33)  
Training 300 (21) 59 (21) 38 (14)  
College 461 (33) 106 (37) 99 (37)  
Missing 143  17  31   
Employment Status        
Working (full or part time) 852 (58) 176 (60) 139 (49) 0.032 
Not working  117 (8) 15 (5) 19 (7)  
Retired 317 (22) 65 (22) 73 (26)  
Student/ homemaker 180 (12) 36 (12) 54 (19)  
Missing 88  9  17   
Marital status        
Partnered 805 (54) 161 (55) 149 (51) 0.707 
Previously partnered 207 (14) 36 (12) 37 (13)  
Single/ other 469 (32) 98 (33) 105 (36)  
Missing 73  6  11   
Care pathway        
Emergency Room 346 (22) 179 (60) 42 (14) <0.001 
Admitted to hospital 588 (38) 109 (36) 153 (51)  






Table 2 (continued)  
 N (%)     
 Study sample GOSE 8a GOSE 8b  p 
 (n=1554) (n=301) (n=302)  
ASA Pre-injury Physical Health         
Healthy patient 943 (61) 183 (61) 205 (69) 0.159 
Mild systemic disease  469 (30) 93 (31) 73 (24)  
Severe systemic disease 129 (8) 22 (7) 21 (7)  
Missing 13  3  3   
Cause of injury        
Road traffic accident 671 (44) 97 (33) 109 (37) 0.549 
Fall 644 (42) 150 (51) 137 (46)  
Violence/assault 87 (6) 21 (7) 26 (9)  
Other 124 (8) 29 (10) 25 (8)  
Missing/ unknown 28  4  5   
GCS score at baseline        
3-8 224 (15)   28 (10) <0.001 
9-12 107 (7)   29 (10)  
13-15 1181 (78) 301 (100) 227 (80)  
Missing 42    18   
CT Imaging abnormality        
Absent 654 (44) 301 (100) 55 (21) <0.001 
Present 843 (56)   213 (79)  
Missing/ uninterpretable 57    34   
Head & neck AIS1        
No injury/ Minor injury 284 (18) 131 (44) 27 (9) <0.001 
Moderate injury 231 (15) 99 (33) 39 (13)  
Serious injury 523 (34) 63 (21) 148 (49)  
Severe injury 271 (17) 5 (2) 52 (17)  
Critical injury/ unsurvivable injury 245 (16) 3 (1) 36 (12)  
Major extracranial injury2        
Absent 1029 (66) 254 (84) 225 (75) 0.004 
Present 525 (34) 47 (16) 77 (26)  
GOSE at six months        
3/4  Severe Disability 115 (7)      
5      Lower Moderate Disability 184 (12)      
6      Upper Moderate Disability 250 (16)      
7      Lower Good Recovery 402 (26)      
8      Upper Good Recovery 603 (39) 301 (100) 300 (100)  
1Head & neck AIS = maximum Abbreviated Injury Score for head, neck and cervical regions. 
2Any non-head & neck AIS ≥ 3 (serious injury) 
 
Raw scores for assessments of the reference group were compared with norms predicted from the 
healthy population (see supplementary Table S4). For some cognitive tests the reference group 
scores are almost identical to the predicted scores (Trail Making A and B, RTI Choice reaction time, 
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SOC problems solved), while for others they are better (RTI movement time, RVP latency, SWM 
Between Errors) or worse (PAL total errors, RAVLT, RVP A prime). Overall, there are no systematic 
trends that would indicate cognitive impairment in the reference group. The SF-12v2 summary score 
means for the reference group were close to norms. 
Percentages of scores one SD or more below the reference group mean are given in Table 3. The 
scores are based on z-scores of transformed variables and have not been adjusted for covariates. 
The expectation from the normal distribution is that 16% of scores will be one SD or more below the 
mean. As can be seen, tests for the reference group conform closely to expectation (13% to 20%), 
while the percentages of clinically significant scores for the most disabled groups (GOSE 3/4 and 
GOSE 5) are always greater than 16% (20% to 59%).  
Table 3. Number (percentage ±95% confidence interval) of standardized test scores 1 SD or more below the mean for the 
reference group (GOSE 8a). The expected value from the normal distribution is 16%. 
 GOSE Category 
 
3/4 5 6 7 8b 8a Total 
PAL Total Errors Adjusted 47(44%±9%) 51(28%±6%) 47(19%±5%) 92(23%±4%) 57(19%±4%) 53(18%±4%) 347(23%±2%) 
RAVLT Total recall of principal list 61(59%±9%) 58(34%±7%) 54(22%±5%) 108(28%±4%) 73(25%±5%) 48(17%±4%) 402(27%±2%) 
Trail Making Part A time (secs) 63(59%±9%) 62(35%±7%) 43(18%±5%) 91(23%±4%) 72(25%±5%) 44(15%±4%) 375(25%±2%) 
Trail Making Part B time (secs) 52(53%±10%) 53(31%±7%) 49(20%±5%) 78(20%±4%) 68(23%±5%) 41(14%±4%) 341(23%±2%) 
RTI Choice Reaction Time (msec) 49(48%±10%) 58(33%±7%) 34(14%±4%) 78(20%±4%) 49(17%±4%) 43(16%±4%) 311(22%±2%) 
RTI Movement Time (msec) 42(41%±9%) 48(27%±7%) 38(16%±5%) 74(19%±4%) 31(11%±4%) 37(14%±4%) 270(19%±2%) 
RVP A prime 37(48%±11%) 54(35%±7%) 51(23%±5%) 76(22%±4%) 51(19%±5%) 40(15%±4%) 309(23%±2%) 
RVP latency (msec) 33(43%±11%) 44(28%±7%) 40(18%±5%) 63(18%±5%) 49(18%±5%) 36(13%±4%) 265(20%±2%) 
AST Total correct 51(51%±10%) 54(31%±7%) 40(17%±5%) 103(27%±4%) 60(21%±5%) 53(19%±5%) 361(25%±2%) 
AST latency (msec) 39(39%±9%) 44(25%±6%) 39(17%±5%) 65(17%±4%) 40(14%±4%) 46(16%±4%) 273(19%±2%) 
SWM Between errors 35(37%±10%) 35(20%±6%) 36(15%±5%) 75(20%±4%) 55(19%±4%) 32(11%±4%) 268(18%±2%) 
SOC Problems solved 29(35%±10%) 33(20%±6%) 44(19%±5%) 81(22%±4%) 64(23%±5%) 57(20%±5%) 308(22%±2%) 
 
The results of omnibus comparisons of outcome categories adjusting for age, sex and level of 
education are given in Table 4. Estimated means and 95% CIs for each measure are shown in Figure 
1, after adjusting for covariates. As can be seen, there are differences in cognitive performance 
across groups for all measures. Overall effect sizes were small to medium (Table 4), and greatest for 
tests involving processing speed (RTI Decision Time and Trail Making Test A and B) and learning and 
memory (PAL and RAVLT), followed by tests of sustained attention (RVP) and attention switching 





Table 4. Summary of ANCOVA for the overall difference across GOSE categories adjusted for age, sex, and 
education level. Statistics are based on pooling after multiple imputation of education level.  
Measure N F (df1, df2) P  ηp
2 
PAL Total errors adjusted  1525 16.41 (5,1053801) <0.0001 0.052 
RAVLT total 1489 14.74 (5, 186787) <0.0001 0.048 
Trail Making Part A 1510 21.44 (5, 402889) <0.0001 0.067 
Trail Making Part B 1473 20.71 (5, 41897) <0.0001 0.067 
RTI Decision time 1443 17.28 (5, 371581) <0.0001 0.057 
RTI Movement time 1443 11.94 (5, 907334) <0.0001 0.040 
RVP A prime 1350 9.79 (5, 147074) <0.0001 0.035 
RVP latency 1350 11.77 (5, 163509) <0.0001 0.042 
AST Total correct 1467 9,12 (5, 46026) <0.0001 0.031 
AST latency 1467 12.06 (5, 884657) <0.0001 0.040 
SWM Between errors 1464 6.49 (5, 397235) <0.0001 0.022 
SOC problems solved 1421 3.62 (5, 182029) 0.0026 0.013 
Notes: ηp
2 = partial eta-squared 
 
 
Figure 1 indicates generally monotonic associations between cognitive test performance and order 
of outcome categories. Lower cognitive performance was particularly evident in patients who were 
dependent (GOSE 3 or 4) or who were unable to participate in one or more major life activities 
(GOSE 5). As can be seen from Figure 1, these two groups consistently have poorest performance. 
On many measures (PAL, RAVLT, TMT A and B, RVP latency, RTI and AST), there are clear differences 
between GOSE 5 and GOSE 6 (i.e. the CIs do not overlap). In contrast, performance for the groups 
with GOSE 6, 7, and 8 was surprisingly similar across categories (i.e. many of the CIs overlap by 50% 
or more).  
_______________________________________ 
Figure 1 about here 
_______________________________________ 
 
Overall effect sizes from ANCOVA for the three summary measures were medium to large: 0.11 for 
cognition (F=36.98, df 5, 36425, p<.0.0001), 0.25 for the physical health summary (F=100.74, df 5, 
110351, p<0.0001), and 0.13 for the mental health summary (F=45.22, df 5, 2680243, p<0.0001). 
Figure 2 displays z-score differences from group GOSE 8a.  
_______________________________________ 
Figure 2 about here 
_______________________________________ 
 
Inspection of Table 3 and Figure 1 suggests small but systematic deficits in cognitive performance in 
GOSE group 8b compared to 8a. The following pairwise comparisons between these groups met the 
Benjamini and Hochberg criteria (raw p values in brackets): Trail Making Part A (p=0.007), cognition 
composite (p=0.013), RAVLT (p=0.027), AST correct (p=0.042), RTI Reaction Time (p=0.050), RVP 
latency (p=0.067), Trail Making Part B (p=0.077), and SWM Between errors (p=0.079). There are thus 
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systematic differences in cognitive performance between Groups 8a and 8b. In contrast the groups 
had similar the physical and mental health summary scores (p=0.417 and 0.956, respectively).  
DISCUSSION 
Cognitive impairment is believed to be a key driver of disability, but important gaps remain in our 
understanding of this relationship. The current study provides two key pieces of information about 
this relationship: (1) it identifies cognitive domains most strongly related to function in daily life, and 
(2) it establishes where cognitive deficits most impact on difference between levels of function.  
Prior to discussing the main findings, it is appropriate to consider the issue of missing data.18 Much 
past work on cognition in TBI has used test completion as an inclusion criterion (either explicitly or 
implicitly), and thus provides little information on completion rates.  In clinical trials that have 
included cognitive outcomes as an endpoint, completion by around half of patients recruited has 
been reported.19,20  We found that completion of cognitive assessments was strongly related to 
outcome on the GOSE, a result that echoes a report by Clifton and colleagues.21  In their group of 
110 cases included in the Traumatic Coma Data Bank there was 6 month cognitive assessment in 
60% of patients with Good Recovery while only 6% of patients with Severe Disability were tested. 
Explanations include cognitive impairment that prevents testing and logistical factors relating to 
availability of patients who are dependent.19   Particular caution is therefore needed concerning 
interpretation of findings for the severely disabled category (as indicated in Figure 2). The 
comparison of completers and non-completers suggests other factors, such as level of education,  
play a role in follow-up but the differences here appear relatively minor. 
 
Cognitive domain and function in daily life 
The results provide novel insight into cognitive test performance at different levels of disability, and 
highlight the particular importance of processing speed in function in daily life.  TMT part A and RTI 
Decision Time are both measures of processing speed and were among tests showing the greatest 
differences between outcome categories. TMT part B adds  task switching demands, but this did not 
appear to make the task more sensitive. We conclude that processing speed has the strongest 
overall relationship with functional outcome in current analyses. In addition to processing speed, 
learning and memory and aspects of attention were related to functional outcome, while two 
measures of executive function showed the smallest differences across categories of outcome. This 
cognitive profile replicates that reported by Salmond et al 22 and may reflect cholinergic dysfunction. 
Impairment of processing speed and on tasks such as SOC implicates other neurochemical systems, 
including dopaminergic pathways.23  
Our findings are concordant with previous evidence that processing speed particularly influences 
functional outcome at 12 months post-injury.24 Furthermore, Ponsford and colleagues25 found that 
slow processing speed was the area of cognition most strongly related to the GOSE 10 years after 
TBI, implying that this deficit has a long-term impact.26  
It is thought that slowing disrupts timing and synchrony of mental operations and has a general 
impact on cognitive function.23 Processing speed after TBI is thus a prime target for pharmaceutical 
interventions,23,27 and the current study supports the potential value of cognitive enhancers for 
improving function in daily life. The critical impact of processing speed in this context may be 
explained by the widely distributed neuroanatomical network which underpins it, and hence makes 
it vulnerable to diffuse pathologies.28-30 
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Cognition and level of functional recovery 
The  study allowed cognitive performance across levels of disability to be examined in greater detail 
than previously. The most disabled groups showed clearest evidence of poor cognitive performance. 
In addition, as already noted, many severely disabled patients did not complete testing, consistent 
with profound cognitive impairment in this group. There were also clear decreases in performance in 
patients with GOSE 5. Individuals in this category are unable to participate in one or more major 
areas of activity, such as work or social and leisure activities. Cognitive assessment in these cases can 
identify particular barriers to functional recovery, and areas that can be targeted by rehabilitation.31  
A surprising finding is that  cognitive performance is similar across higher levels of functional 
recovery (GOSE 6 to 8b), explaining why the amount of variance in functional outcome accounted for 
by cognition can be modest.5,7 In these groups, decreases in performance are small, and any 
evidence of impairment limited to a minority. It appears to have been assumed in the past that the 
relationship between the GOSE and cognition is essentially linear. It has been suggested, for 
example, that cognitive testing could help to improve the granularity of upper categories of 
functional outcome.32 However, our findings argue against such a conception of the relationship. 
The comparison of group GOSE 8b with the reference group shows that some cognitive impairment 
is present even in patients reporting complete recovery. The influence of cognitive impairment on 
function may be attenuated by active compensation.33 For example, the person with cognitive 
slowing may adapt by taking greater time and effort to complete tasks, show increased 
compensatory recruitment (e.g. of the prefrontal cortex) in processing speed tasks,34 and report 
more fatigue,35  in keeping with greater effort. Subtle changes in cognition are thus still likely to be 
consequential, and could, for example, be a source of stress in demanding work settings. In the long-
term cognitive decline will reduce reserve, and may make the individual vulnerable to the effects of 
degenerative illness in later years.36 Formal cognitive assessment is valuable to establish whether 
impairment is present, even in individuals who have apparently recovered well. 
Diffuse white matter changes are a key neuropathological substrate for both cognitive deficits and 
poor daily life outcomes.37 Newcombe and colleagues 38 found that diffusion tensor imaging (DTI) 
abnormalities were related to the GOSE, and report findings qualitatively very similar to the 
trajectory shown for cognitive impairment in Figure 2. We therefore hypothesize that cognitive 
impairment is a major mediator of the relationship between diffuse white matter damage and poor 
functional outcome after TBI.  
Comparison of cognitive, physical, and mental health outcomes 
In contrast to the cognitive outcomes, there are clear differences in mental and physical health-
related outcomes at the upper levels of recovery. Comparison with the SF-12v2 physical health 
summary argues against the idea that the relative coarseness of the GOSE explains absence of 
cognitive differences at upper levels of recovery: participants with GOSE 8a and GOSE 8b are close to 
the healthy norm, and thus unlikely to include a substantial subgroup with functional limitations. 
Furthermore, there are clear differences in SF-12v2 mental and physical health outcomes across 
GOSE categories 6 to 8b, and no overlap that would explain the similarity in cognitive performance 
between these groups.  
Overall, the findings indicate contrasting relationships of cognition and mental health with functional 
outcome after TBI.  Cognitive impairment appears to be a key influence on disability at lower levels 
of outcome. On the other hand, differences in aspects of mental health are prominent at upper 
levels of recovery,8 and seem likely to play a role in whether the person achieves a complete 
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recovery. Although relationships between function in daily life and mental health will be bi-
directional, understanding mental health problems provides a clear focus for treatment which may 
also improve functional outcome.  
The physical health component of the SF-12v2 tracks outcome across GOSE categories, confirming a 
close relationship between these assessments of global functional outcome.39  It is also likely that 
aspects of physical health, such as continuing effects of extracranial injury, are drivers of overall 
functional outcomes, particularly in individuals with mild injuries.40 
These findings are important in the context of developing multidimensional outcome measures 
which characterise outcome beyond the GOSE.41 Our data indicate that assessments of cognitive 
performance and psychological health are likely to have distinct contributions across different parts 
of the outcome spectrum. The findings thus strongly support separate evaluation of cognition, 
mental health, and function in daily life after TBI as multidimensional descriptors of outcome.  
Limitations and future directions 
The reference group was at the very mildest end of the spectrum but may nonetheless have 
included individuals with impaired cognitive performance, and this would result in underestimation 
of the extent of impairment.  Use of additional markers of brain injury, such as post-traumatic 
amnesia, MR imaging, or biomarkers could help to define a reference group.  The use of an internal 
comparison group provides a strong control for factors associated with TBI, including variables not 
explicitly measured such as accident trauma and aspects of TBI care. While acknowledging that it is a 
conservative approach, the comparison provides even greater confidence in the differences found. 
As already discussed, a further limitation of the study concerns missing outcomes. Since this 
inevitably includes some individuals with the greatest cognitive impairment, the effect will be to lead 
to underestimation of cognitive impairment in the most disabled categories of outcome.  
To our knowledge, this is the first study of cognition in TBI large enough to describe in detail 
performance at different levels of functional outcome.  Unexpectedly, we found little difference in 
cognitive performance at upper levels of outcome. This raises two key issues for future research. The 
first concerns the drivers of outcome and whether emotional and mental health factors play a key 
role at the upper end of functional recovery.42  The second relates to the nature and significance of 
cognitive impairment in these patients. The instruments we used address cognition without the 
contextual stresses of everyday life. Further, they do not account for increased cognitive fatigability 
reported by many patients, and provide only limited measures of the effortfullness of these tasks,43 
which have identifiable neuroanatomic correlates.44 Tests of “hot cognition”45 and measures of 
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Figure legends 
Figure 1. GOSE outcome categories and cognitive performance. Means and 95% CIs of z-scores. 
Abbreviations: Dec = decision time, Mov = movement time, Lat = latency, Cor= correct. 
Figure 2. Contrasting relationships with functional status. Data are differences (z-scores) from 
reference (dashed line) graphed as means and 95% confidence intervals. The SF-12v2 Physical 
Component Summary (Physical) and the GOSE are in good agreement, as indicated by the near 
straight line relationship. The cognition composite (Cognition) strongly separates lower levels of 
outcome, but not upper; although some cognitive impairment is present even among patients 
reporting complete recovery.  The SF-12v2 Mental Component Summary  (Mental) does not 
distinguish between the lowest categories, but strongly differentiates more favourable outcomes. 
The shaded area covers data points where test completion rates were relatively low and additional 
caution is required concerning interpretation. 
